The National Agency for Food and Drugs Administration and Control (NAFDAC) has raised an alarm regarding five oral liquid medications discovered in the Maldives and Pakistan, also found in Belize, Fiji, and the Lao People’s Democratic Republic.
These compromised products—ALERGO Syrup, EMIDONE Suspension, MUCORID Syrup, ULCOFIN Suspension, and ZINCELL Syrup—comprise 23 batches, all sourced from PHARMIX LABORATORIES (PVT.) LTD in Pakistan.
Testing conducted by various authorities revealed hazardous levels of diethylene glycol and ethylene glycol contaminants in the ALERGO syrup, prompting serious concerns.
The discovery led to a broader investigation by the Drug Regulatory Authority of Pakistan, resulting in the suspension of all oral liquid medication production by PHARMIX LABORATORIES and a recall notice for the five identified products.
Both diethylene glycol and ethylene glycol pose severe health risks, including abdominal pain, vomiting, altered mental state, and acute kidney injury, potentially leading to fatal outcomes if ingested.
Despite not being registered by NAFDAC, these products might have found their way into other markets, potentially including Nigeria.
NAFDAC emphasizes the urgency of vigilance within the supply chain to prevent the distribution, sale, and use of these compromised cough syrups.
Importers, distributors, retailers, and consumers are urged to verify the authenticity of medical products obtained from authorized sources.
Additionally, NAFDAC advises against using the listed products and encourages individuals in possession of these items to surrender them to the nearest NAFDAC office.
Those who have used these products and experienced adverse effects are strongly advised to seek immediate medical assistance.
NAFDAC urges healthcare professionals and consumers to report any suspicions of adverse drug reactions or substandard medicines.
Reports can be made through various channels, including a toll-free number, email, the NAFDAC website, and dedicated applications for Android and iOS devices.
Swift reporting and heightened awareness are crucial in safeguarding the integrity of medicinal products within the Nigerian market.
